Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
暂无分享，去创建一个
V. Sondak | J. Sosman | J. Kirkwood | F. Hodi | H. Kluger | Carrie Lee | L. Hutchins | M. Albertini | D. Lawrence | U. Rao | O. Hamid | D. Minor | G. Cohen | Z. Eroglu | K. Kendra | L. Flaherty | A. Tarhini | Sandra J. Lee | T. Petrella | H. Streicher | H. Koon